ClearSky Medical Diagnostics offers a portfolio of non-invasive devices for diagnosing and monitoring complex neurological conditions, including Parkinson's,Huntington's, and dementia.
ClearSky utilises its proprietary 'white-box' machine learning algorithms, which simulate real-world human specialists and enable diagnoses based on movement biomarkers, spanning from hand movements to eye saccades.
Over the years, ClearSky has supported renowned medical centres and specialists for their clinical research with its CE-marked devices.
ClearSky is now expanding its portfolio by developing an innovative diagnostic solution to detect Mild Cognitive Impairment (MCI).
ClearSky continues to pursue partnerships with healthcare professionals and pharmaceutical and medical technology companies to provide efficient and user-friendly patient-centric diagnostic solutions.
PD-Monitor, a CE marked medical device that provides an objective measure of finger tapping in Parkinson’s motor examination.
Evaluation of bradykinesia in Parkinson’s Disease using a computerised evolutionary algorithm.
Clinically 'slight' bradykinesia in Parkinson's disease is accurately detected using evolutionary computation analysis of finger tapping
Objective assessment of bradykinesia in Parkinson’s disease using evolutionary algorithms: clinical validation
A kinematic analysis of finger tapping in dystonia
LID-Monitor,a CE marked medical device that provides at-home 24-hour continuous monitoring of levodopa induced dyskinesia.
A New Evolutionary Algorithm-Based Home Monitoring Device for Parkinson’s Dyskinesia
Cost-Effectiveness Analysis of a Device to Monitor Levodopa-Induced Dyskinesia in Parkinson’s Patients
Classification and Characterisation of Movement Patterns During Levodopa Therapy for Parkinson’s Disease
Developing a new home monitoring device for dyskinesia in Parkinson's disease
Simvastatin as a neuroprotective treatment for Parkinson’s. The study, called PD-STAT, is taking place at 23 NHS hospitals across the UK and is led by the Peninsula Clinical Trials Unit at Plymouth University and sponsored by Plymouth Hospitals NHS Trust.
Chief Investigator: Dr Camille Carroll, Peninsula Medical School, University of Plymouth
Sites (in 6 of 22): Derriford Hospital, Plymouth; Royal Cornwall Hospital, Truro; St Peter’s Hospital, Chertsey; Royal Free Hospital, London; John Radcliffe Hospital, Oxford; Kings College Hospital, London
Status: Concluded March 2020 (due to COVID-19)
Azathioprine, an immunosuppressor. ClearSky’s PD-Monitor is being used in the AZA-PD clinical trial, led by the University of Cambridge’s Centre for Parkinson-Plus. The trial is addressing precisely how azathioprine, an immunosuppressive medication, interacts with the immune system in Parkinson’s with the aim of slowing brain cell damage and the progression of clinical symptoms.
Chief Investigator: Dr Caroline Williams-Gray, University of Cambridge.
Sites: Cambridge University Hospitals NHS Trust,
Exenatide, a receptor agonist. The PD-Monitor is being used in a clinical trial in patients with Parkinson’s, of a drug called exenatide, which is already licensed for the treatment of patients with type 2 diabetes. The trial will involve 200 participants with Parkinson’s from 15 hospital centres across the UK.
Chief investigator: Dr Thomas Foltynie, UCL Queen Square Institute of Neurology
Sites (in 2 of 6): King’s College Hospital NHS Foundation Trust; University College London Hospitals NHS Foundation Trust (UK)
Patients: 200 total